World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
41246
World Ranking
18962
National Ranking
107

Werner Scheithauer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Werner Scheithauer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 415 publications — 42nd percentile

42% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Werner Scheithauer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Werner Scheithauer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Werner Scheithauer was affiliated with the Medical University of Vienna in Austria. Their research focused primarily on the field of Medicine, with a significant emphasis on Oncology. The scientist contributed extensively to academic literature, authoring 54 publications in the main field of Medicine.

Their work spanned several subfields, notably:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Hepatology
  • Cancer Research
  • Pathology and Forensic Medicine

The main research topics covered in their publications included:

  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Genetic factors in colorectal cancer

Werner Scheithauer co-authored frequently with several researchers, among whom the most notable were:

  • Sebastian Stintzing (14 publications)
  • Thomas Decker (13 publications)
  • Alexander Kiani (13 publications)
  • Christoph Kahl (13 publications)
  • Dominik Paul Modest (13 publications)

Their research appeared in various respected scientific journals, with recurring publications in:

  • Journal of Clinical Oncology (6 publications)
  • European Journal of Cancer (3 publications)
  • Annals of Oncology (3 publications)
  • British Journal of Cancer (2 publications)
  • Journal of Clinical Medicine (1 publication)

Selected recent papers by Werner Scheithauer included:

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2023, Journal of Clinical Oncology)
  • FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial (2020, British Journal of Cancer)
  • Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients (2020, Journal of Clinical Medicine)
  • Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer (2020, Thrombosis Research)
  • Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group (2020, Annals of Oncology)

Best Publications

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

    Volker Heinemann;Ludwig Fischer von Weikersthal;Thomas Decker;Alexander Kiani

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

    Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt

  • Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer

  • Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

    David Cunningham;Ian Chau;Deborah D. Stocken;Juan W. Valle

  • Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    Richard Herrmann;György Bodoky;Thomas Ruhstaller;Bengt Glimelius

  • Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

    Eric Van Cutsem;Walter L. Vervenne;Jaafar Bennouna;Yves Humblet

  • Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

    Thierry André;Armand De Gramont;Dewi Vernerey;Benoist Chibaudel

  • nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    David Goldstein;Robert Hassan El-Maraghi;Pascal Hammel;Volker Heinemann

  • Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

    CH Kohne;D Cunningham;F Di Costanzo;B Glimelius

  • Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Brigit Gruenberger;Dietmar Tamandl;Johannes Schueller;Werner Scheithauer

  • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

    Sebastian Stintzing;Sebastian Stintzing;Dominik P Modest;Dominik P Modest;Lisa Rossius;Markus M Lerch

  • Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    I Virgolini;M Raderer;A Kurtaran;P Angelberger

  • Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

    W. Scheithauer;J. McKendrick;S. Begbie;M. Borner

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

Frequent Co-Authors

Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München
Andreas Jung
Andreas Jung University of Zurich
Markus Raderer
Markus Raderer Medical University of Vienna
Thomas Decker
Thomas Decker University of Vienna
Christoph C. Zielinski
Christoph C. Zielinski Medical University of Vienna
Bengt Glimelius
Bengt Glimelius Uppsala University
Aimery de Gramont
Aimery de Gramont Grenoble Alpes University
Thierry André
Thierry André Université Paris Cité
Burghardt Wittig
Burghardt Wittig Freie Universität Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine isn’t limited to becoming a physician. There are numerous online degree options that can launch or advance your healthcare journey while offering flexibility and affordability.

Entry-level positions in the medical field, such as medical billing and coding, are in high demand. If you’re interested in joining the healthcare sector quickly or at a lower cost, consider enrolling in a low cost medical coding and billing online program. These programs equip you with essential skills to manage healthcare records and insurance claims.

For those aspiring to become registered nurses or advance their nursing careers, there are cheapest online nursing programs and affordable np programs available online. Nurse practitioner programs, in particular, prepare you for advanced clinical roles and increased responsibility.

Ambitious nursing professionals can further their expertise with online nursing phd programs. A PhD opens doors to leadership, research, and teaching positions in the healthcare industry.

Best Scientists Citing Werner Scheithauer

Recently Published Articles